Merck & Co., Inc.

Merck & Co., Inc.

MRK

$148.66

Updated: 04/11/2026, 18:42:44

Market Cap
$366.65B
Sector
Healthcare
Industry
Drug Manufacturers - General
Country
US

No historical data available

Company Profile

Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.

USD
NYSE
CEO: Robert Davis
Employees: 74,000
https://www.merck.com
Asset Summaries
Latest generated summaries for MRK

No summaries found.

Detailed business
Evidence-backed facts extracted from the latest official annual filing.
MRK-10-k-fy2025.html5.0 MBtext/htmlENFiled 24/02/2026Period ended 31/12/2025

Business monitoring

Reported and calculated KPIs plus operational exposure disclosed in the FY 2025 filing.

Evidence-backed · 40 KPI observations

Revenue

N/A

FY — · Reported

Net income

$18.3B

FY 2025 · Reported

Gross margin

N/A

FY — · Reported

Free cash flow

$12.4B

FY 2025 · Calculated

R&D intensity

N/A

FY — · Reported

Share repurchases

$5.1B

FY 2025 · Reported

Earnings and cash generation
USD billions, directly sourced from inline XBRL; free cash flow is operating cash flow less capex.
Profitability and reinvestment
Margins and R&D as a percentage of revenue.
Top products and services
Products and services mentioned in the filing; a quantitative sales breakdown was not disclosed.

Other offerings mentioned without separate sales

Key products generating profits and cash flows

Area-level product sales are displayed only when the filing reports a product × geography breakdown. Regional totals are not allocated across products by estimation.

Geographic footprint
What the filing identifies, separated by location role so partner manufacturing is not presented as Apple-owned factories.
1 named headquarters
0 manufacturing countries
0 individually named factories

Map layer

Pins show disclosed operations. The heatmap colors the filing’s reported geographies; regional figures shade the region and are not estimates for each country.

No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosure
Named headquarters Manufacturing partner country

Only locations and quantities explicitly supported by the filing are displayed. A country-level manufacturing percentage or product allocation is shown only when the source discloses it; materiality scores are never presented as production shares.

How the business makes money

U.S. wholesaler distribution programs with inventory-visibility fees

U.S. wholesalers earn fees under distribution programs providing inventory visibility and performance metrics.

90%
Source evidence
“the wholesalers to earn fees upon providing visibility into their inventory levels, as well as by achieving certain performance parameters such as inventory management, customer service levels, reporting of data, and providing central product distribution.”

Key products generating profits and cash flows

Key products: Keytruda, Gardasil/Gardasil 9, Lynparza, Winrevair, Bravecto.

95%
Source evidence
“depends largely upon the continued profitability of the Company's key products, such as Keytruda, Gardasil/Gardasil 9, Lynparza, Winrevair, and Bravecto.”

Bravecto share of Animal Health sales

2025 Bravecto family sales of $1.1 billion, 18% of Animal Health segment sales.

97%
Source evidence
“in 2025, sales of the Bravecto family of products were $1.1 billion, which represented 18% of the Company's Animal Health segment sales.”

Operations and dependencies

Foreign currency revenue hedging program

Revenue hedging primarily for euro, Japanese yen and Chinese renminbi exposures

94%
Source evidence
“reduce the variability caused by changes in foreign exchange rates ... primarily the euro, Japanese yen and Chinese renminbi”

Positioning and strategy

Cidara acquisition January 2026

January 2026 acquisition of Cidara for ~$9.2B; lead candidate MK-1406 influenza antiviral; ~$9.0B IPR&D charge expected Q1 2026

97%
Source evidence
“In January 2026, Merck acquired Cidara, a biotechnology company developing drug-Fc conjugate (DFC) therapeutics, for approximately $9.2 billion”

MK-8690 rights agreement with Falk

$150M upfront payment to Falk for global rights to MK-8690 (Nov 2025)

93%
Source evidence
“Merck made a $150 million upfront payment, which the Company recorded as a charge to Research and development expenses in 2025”

LaNova MK-2010 technology transfer payment

$300M payment to LaNova on completion of MK-2010 technology transfer (July 2025)

90%
Source evidence
“Merck made a $300 million payment to LaNova that was recorded as a char”

Daiichi Sankyo ADC collaboration economics

Daiichi Sankyo collaboration on ADCs; $170M upfront received for gocatamig expansion (Aug 2024)

93%
Source evidence
“In August 2024, Merck and Daiichi Sankyo expanded their agreement to include gocatamig (MK-6070) ... Merck received an upfront cash payment of $170 million from Daiichi Sankyo”

Risks, financing, and outlook

Blackstone funding arrangement for MK-2870

Blackstone will pay Merck up to $700M in Q4 2026 to fund sac-TMT (MK-2870) development costs

95%
Source evidence
“Blackstone will pay Merck up to $700 million in the fourth quarter of 2026 ... to fund a portion of the Company’s development costs for MK-2870, sacituzumab tirumotecan (sac-TMT)”

2025 Restructuring Program

2025 Restructuring Program: ~$3.0B cumulative pretax costs, largely complete by end of 2027

95%
Source evidence
“The cumulative pretax costs to be incurred by the Company to implement the program are estimated to be approximately $3.0 billion, of which approximately 60% will be cash”

2024 Restructuring Program

2024 Restructuring Program: ~$4.0B cumulative pretax costs through 2031

94%
Source evidence
“The actions contemplated under the 2024 Restructuring Program are expected to be substantially completed by the end of 2031, with the cumulative pretax costs ... estimated to be approximately $4.0 billion”

IRA government price setting selections

IRA price setting: Januvia (2026), Janumet/XR (2027), Lenvima (2028), Keytruda expected (2029).

96%
Source evidence
“the Company expects that in 2027 HHS will include Keytruda in a subsequent selection of products to undergo IRA price setting, with such price to become effective on January 1, 2029”

EU reference pricing and HTA regime

EU cost containment via reference pricing and HTAs (HTAR JCAs phased 2025/2028/2030); new EU pharma legislation may allow two-year exclusivity reduction for supply failures.

92%
Source evidence
“The HTAR applies to all new active substance oncology products and advanced therapy medicinal products, including cell and gene therapies, beginning January 2025; to new active substance orphan medicinal products beginning January 2028; and to all products approved via the centralized procedure beginning in 2030.”

IRA Drug Price Negotiation Program selections

HHS/CMS selected Januvia (price effective 1/1/2026), Janumet/Janumet XR (1/1/2027), Lenvima (1/1/2028); Merck expects Keytruda will be selected in 2027 with price effective 1/1/2029.

98%
Source evidence
“the Company expects that Keytruda will be selected in 2027 for government price setting, which would become effective on January 1, 2029, and the Company expects that, as a result, U.S. sales of Keytruda will decline materially after that time.”

China Gardasil sales decline

Significantly lower Gardasil/Gardasil 9 sales in China in 2025; no material increase expected in 2026.

98%
Source evidence
“The Company's business in China experienced significantly lower sales of Gardasil/Gardasil 9 in 2025 and the Company expects that sales of Gardasil/Gardasil 9 in China will not materially increase in 2026.”

US loss of exclusivity: Bridion, Januvia, Janumet

Bridion LOE July 2026; Januvia/Janumet LOE May 2026; Janumet XR LOE July 2026.

98%
Source evidence
“Bridion will lose market exclusivity in the U.S. in July 2026... Januvia and Janumet will lose market exclusivity in the U.S. in May 2026 and Janumet XR will lose market exclusivity in the U.S. in July 2026.”

Keytruda biosimilar competition timeline

Keytruda US biosimilar competition could begin December 2028; EU LOE expected 2031.

97%
Source evidence
“the Company expects that sales of Keytruda will be materially negatively impacted by biosimilar competition between 2028 and 2029... the Company also expects to lose market exclusivity in Europe for Keytruda in 2031 following compound patent expiration.”

China VBP price pressure

China VBP tendering produced average price reductions of more than 50% on mature products.

93%
Source evidence
“Mature products that have entered into the latest rounds of VBP had, on average, a price reduction of more than 50%.”

Currency and interest rate market risk

Exposure to currency and interest rate fluctuations; Argentina experiencing hyperinflation.

92%
Source evidence
“Argentina is currently experiencing hyperinflation, which is affecting the Company's operations in that market.”

US pricing and rebate pressures

Medicaid rebate cap elimination, 340B growth, and state price boards negatively impact performance.

92%
Source evidence
“increased utilization of the 340B Federal Drug Discount Program and restrictions on the Company's ability to identify inappropriate discounts are having a negative impact on the Company's performance.”

Animal health disease outbreak risk

Avian Influenza or African Swine Fever outbreaks could hurt Animal Health results and halt site production.

90%
Source evidence
“the outbreak of disease carried by animals, such as Avian Influenza or African Swine Fever, could lead to their widespread death”

Biologics and vaccines manufacturing complexity

Biologics/vaccines require long lead times and complex manufacturing; inventory write-down risk.

90%
Source evidence
“Biologics and vaccines require long manufacturing lead times, sometimes requiring planning years in advance of demand, which could increase the risk of inventory write-downs”

Third-party reliance and outsourcing

Reliance on third parties for development, manufacturing, commercialization and IT.

90%
Source evidence
“The Company depends on third parties, including suppliers, distributors, alliances with other pharmaceutical and biotechnology companies, and third-party service providers”

Cybersecurity and AI risk

Cyber-attack target; increasing AI use poses inherent risks.

90%
Source evidence
“The Company continues to be a target of cyber-attacks that could lead to a disruption of its worldwide operations, including manufacturing, research and sales operations.”

Medicaid rebate cap elimination risk (American Rescue Plan Act 2021)

Elimination of the Medicaid AMP rebate cap creates risk that rebates exceed 100% of AMP on drugs with high Medicaid utilization.

90%
Source evidence
“As a result of this provision, manufacturers may have to pay state Medicaid programs more in rebates than they received on sales of particular products.”

Vaccine policy and regulatory uncertainty in the US

US vaccine policy changes and CDC schedule alterations could reduce vaccine uptake.

88%
Source evidence
“Changes that have been made to the CDC's recommended immunization schedule which could impact public and private coverage, as well as reduction in state-controlled school immunization requirements, could cause a decline in vaccine uptake.”

Emerging markets pricing and access risks

Emerging markets face price controls, compulsory-license threats, currency controls, and political/trade risks constraining access and growth.

88%
Source evidence
“Governments in many emerging markets are also focused on constraining health care costs and have enacted price controls and measures impacting intellectual property, including in exceptional cases, threats of compulsory licenses, that aim to put pressure on the price of innovative pharmaceuticals or result in constrained market access to innovative medicine.”

Material exposure graph

Keytruda
Revenue Exposure

Keytruda is 49% of total sales and faces biosimilar competition from 2028-2029 and expected IRA price setting effective 2029.

Relevance 98·Dependency 80·Confidence 98
Source evidence
“in the aggregate, in 2025, sales of Keytruda represented 49% of the Company's total sales.”
Keytruda
Revenue Exposure

Keytruda is expected to enter IRA price setting effective 2029, with management expecting materially lower U.S. sales thereafter.

Relevance 95·Dependency 85·Confidence 95
Source evidence
“U.S. sales of Keytruda will decline materially after that time.”
IRA Drug Price Negotiation Program
Regulatory Exposure

IRA price setting directly caps U.S. prices for selected Merck products; management expects material Keytruda U.S. sales decline after its 2029 effective date.

Relevance 95·Dependency 80·Confidence 95
Source evidence
“the Company expects that Keytruda will be selected in 2027 for government price setting, which would become effective on January 1, 2029, and the Company expects that, as a result, U.S. sales of Keytruda will decline materially after that time.”
China
Customer Exposure

Gardasil/Gardasil 9 sales in China fell significantly in 2025 with no material recovery expected in 2026, driving a significant decline in China business.

Relevance 95·Dependency 60·Confidence 97
Source evidence
“As a consequence of the reduced sales of Gardasil/Gardasil 9, the Company's business in China declined significantly.”
Inflation Reduction Act (IRA)
Regulatory Exposure

IRA government price setting covers Januvia (2026), Janumet/Janumet XR (2027), Lenvima (2028), and expected Keytruda (2029), with material US sales decline expected for Keytruda thereafter.

Relevance 90·Dependency 60·Confidence 96
Source evidence
“the Company expects that, as a result, U.S. sales of Keytruda will decline materially after that time.”
Drug pricing regulation
Revenue Exposure

Multi-jurisdictional pricing pressure — IRA price setting, Medicaid rebate cap elimination, state price transparency/Prescription Drug Affordability Boards, EU reference pricing/HTA, and Japan price cuts — collectively pressures Merck's revenue.

Relevance 85·Dependency 70·Confidence 90
Source evidence
“The Company expects that states will continue their focus on pharmaceutical pricing and will increasingly shift to more aggressive price”
Gardasil/Gardasil 9
Revenue Exposure

Lower Gardasil/Gardasil 9 sales drove the significant contraction of Merck's China business in 2025.

Relevance 85·Dependency 65·Confidence 93
Source evidence
“The Company’s business in China experienced significant contraction in 2025 due to lower sales of Gardasil/Gardasil 9.”
IRA Drug Price Negotiation Program
Legal Exposure

Merck is litigating against the U.S. government over the IRA Program, an active legal challenge to a key pricing regulation.

Relevance 75·Dependency 60·Confidence 90
Source evidence
“The Company has sued the U.S. government regarding the IRA’s Program”
U.S. wholesalers
Revenue Exposure

U.S. wholesaler distribution programs with inventory-visibility fees align purchases with underlying demand, reducing channel-inventory distortion risk.

Relevance 70·Dependency 55·Confidence 88
Source evidence
“Through its distribution programs with U.S. wholesalers, the Company encourages wholesalers to align purchases with underlying demand and maintain inventories within certain ranges.”
USD (local-currency sales exposure)
Currency Exposure

Virtually all sales are denominated in local jurisdiction currencies; hedging may be costly and not always successful; Argentina hyperinflation affecting operations.

Relevance 70·Dependency 50·Confidence 90
Source evidence
“the Company operates in multiple jurisdictions and virtually all sales are denominated in currencies of the local jurisdiction.”
Daiichi Sankyo
Technology Dependency

ADC collaboration with Daiichi Sankyo drives substantial R&D spend ($524M in 2025; $5.5B charge in 2023) and future shared profits on ifinatamab deruxtecan and gocatamig.

Relevance 70·Dependency 50·Confidence 90
Source evidence
“Research and development (2) 524 351 5,549”
China
Competitive Exposure

China VBP tendering has driven average price reductions of more than 50% on mature products with generic substitutes.

Relevance 70·Dependency 45·Confidence 92
Source evidence
“Mature products that have entered into the latest rounds of VBP had, on average, a price reduction of more than 50%.”
Bravecto
Revenue Exposure

Bravecto family generated $1.1 billion in 2025, 18% of Animal Health segment sales; negative events would materially affect Animal Health sales.

Relevance 65·Dependency 50·Confidence 95
Source evidence
“in 2025, sales of the Bravecto family of products were $1.1 billion, which represented 18% of the Company's Animal Health segment sales.”
Third-party outsourcing and supply reliance
Supplier Dependency

Dependence on suppliers, distributors, alliances, and IT service providers; failure could materially adversely affect the business.

Relevance 65·Dependency 45·Confidence 88
Source evidence
“Failure of these third parties to meet their contractual, regulatory and other obligations to the Company... could have a material adverse effect on the Company's business.”
US vaccine policy uncertainty
Competitive Exposure

Potential changes to FDA, CDC immunization schedules, and school immunization requirements could reduce vaccine uptake.

Relevance 60·Dependency 35·Confidence 85
Source evidence
“could cause a decline in vaccine uptake.”
Bristol-Myers Squibb
Revenue Exposure

Reblozyl royalty revenue from BMS collaboration reached $525 million in 2025 and will be halved on generic entry or patent expiry.

Relevance 60·Dependency 30·Confidence 92
Source evidence
“Merck receives tiered royalties ranging from 20% to 24% based on sales levels. This royalty will be reduced by 50% upon the earlier of patent expiry or generic entry”
Cidara
Revenue Exposure

$9.2 billion acquisition of Cidara with an expected $9.0 billion IPR&D charge (~$3.65/share) in Q1 2026 for the MK-1406 influenza antiviral.

Relevance 60·Dependency 20·Confidence 95
Source evidence
“Merck expects to record a charge of approximately $9.0 billion to Research and development expenses, or approximately $3.65 per share, in the first quarter of 2026”
euro
Currency Exposure

Merck hedges euro-denominated forecasted sales via its revenue hedging program.

Relevance 55·Dependency 40·Confidence 90
Source evidence
“primarily the euro, Japanese yen and Chinese renminbi”
Japanese yen
Currency Exposure

Japanese yen is a primary currency in Merck's revenue hedging program.

Relevance 50·Dependency 35·Confidence 88
Source evidence
“primarily the euro, Japanese yen and Chinese renminbi”
Moderna, Inc.
Technology Dependency

Joint development and commercialization of intismeran autogene (V940/mRNA-4157) with Moderna; costs and profits shared equally.

Relevance 50·Dependency 30·Confidence 90
Source evidence
“Merck and Moderna share costs and will share any profits equally under this worldwide collaboration.”
Full company information
Latest profile, trading, valuation, and identifier data stored for MRK.
Share price
$148.66
Market cap
$366.65B
Exchange
NYSE
Currency
USD
CEO
Robert Davis
Employees
74,000
IPO date
13/01/1978
Beta
0.222
Last dividend
$0.00
Day range
$146.05 – $148.93
52-week range
$82.01 – $156.92
1-day performance
2.75%
1-year performance
81.26%
Current drawdown (1Y)
-5.27%
CIK
0000310158
CUSIP
58933Y105
ISIN
US58933Y1055
Created
07/12/2025, 05:19:32
Last update
04/11/2026, 18:42:44

Track Merck & Co., Inc. with an AI analyst

See which prediction-market events move MRK, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to MRK from your Railway `news_articles` table.

Is It Worth Investing in Merck (MRK) Based on Wall Street's Bullish Views?

Zacks Investment Research • STOCK • 12/06/2026, 12:31:04

Merck Animal Health to Acquire TARGAN

Business Wire • STOCK • 11/06/2026, 08:45:00

Merck Stock Moves Above 50-Day SMA: Assessing Its Investment Case

Zacks Investment Research • STOCK • 10/06/2026, 11:42:36

Merck & Co., Inc. (MRK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 09/06/2026, 16:22:17

Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study

Business Wire • STOCK • 08/06/2026, 18:30:00

Mizuho Strategist: Healthcare Is Now a Value Sector as Pharma Stocks Underperform Tech

24/7 Wall Street • STOCK • 07/06/2026, 11:30:55

Merck & Co.: Why The Market Is Right To Start Buying Into Post-Keytruda Promise

Seeking Alpha • STOCK • 05/06/2026, 14:25:36

Merck (MRK) Crossed Above the 50-Day Moving Average: What That Means for Investors

Zacks Investment Research • STOCK • 05/06/2026, 12:31:20

Merck & Co., Inc. (MRK) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 04/06/2026, 16:52:54

Merck's Calderasib Gets FDA's Breakthrough Therapy Tag for NSCLC

Zacks Investment Research • STOCK • 01/06/2026, 16:00:28

Can MRK's New Drugs & Pipeline Aid Long-Term Growth Post Keytruda LOE?

Zacks Investment Research • STOCK • 29/05/2026, 13:11:11

FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)

Business Wire • STOCK • 29/05/2026, 08:45:00